CALGENT BIOTECHNOLOGY CO., LTD.
Update：2026/07/22
Industries
Main Industry
Biotechnology
Main Product/Service
Calgent’s drug pipeline includes several novel therapeutic candidates. Their lead asset, CAL056 (Hectinib), is an oral first‑in‑class HECT-domain E3 ubiquitin ligase inhibitor for the treatment of multiple myeloma, which has received Orphan Drug Designati
Founded Year
2019
Unified Business No.
85127916
Status
Active
Number of Employees
0
Total Paid-in
Capital
338,333,340 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Calgent Biotechnology Co., Ltd. is a Taiwan-based biotech startup headquartered in Taipei. Founded in 2019, the company focuses on developing first-in-class small molecule therapeutics to address unmet medical needs. Calgent brings together expertise in translational medicine, pharmacology validation, formulation development, and clinical trial management.
